Inflammatory bowel disease (Crohn%s) & Ulcerative Colitis

Inflammatory bowel disease (Crohn%s) & Ulcerative Colitis

  • May 2015 •
  • 518 pages •
  • Report ID: 4035417 •
  • Format: PDF
Datamonitor Healthcare forecasts strong growth in the IBD market during 2014–23, driven by the lucrative US market, with the impact of new product launches expected to outweigh downward pressure from biosimilar competition.

This report addresses the following questions:

- What impact will biosimilars have on market-leading drugs for IBD and when will key biosimilar launches occur in each market?
- What do surveyed gastroenterologists consider to be the biggest prescribing influences for Crohn’s disease and ulcerative colitis?
- How does biologic prescribing differ for Crohn’s disease and ulcerative colitis and where is the greatest commercial potential?
- What are the remaining unmet needs for Crohn’s disease and ulcerative colitis, and how are their pipelines addressing these needs?
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.